Controlled release of adenosine from core-shell nanofibers to promote bone regeneration through STAT3 signaling pathway

Xin Cheng,1, Gu Cheng,2,b,1, Xin Xing,a, Chengcheng Yin,a, Yuet Cheng,a, Xue Zhou,c, Shan Jiang,d, Fenghua Tao,e, Hongbing Deng,b,e, Zubing Li,a,e

The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST), Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China
bHubei International Scientific and Technological Cooperation Base of Sustainable Resource and Energy, Hubei Key Lab of Biomass Resource Chemistry and Environmental Biotechnology, School of Resource and Environmental Science, Wuhan University, Wuhan 430079, China
cSchool of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
dDepartment of Chemical and Biological Engineering, Iowa State University, Ames, IA 50014, USA
eDepartment of Orthopedics, Renmin Hospital of Wuhan University, Wuhan University, Wuhan 430060, China

ARTICLE INFO

Keywords:
Adenosine
Coaxial electrospinning
Nanofiber
Bone formation
STAT3 signaling pathway

ABSTRACT

Adenosine (Ade) has been identified to stimulate bone formation. However, the use of Ade is severely limited by the accompanying side effects and its very short half-life in vivo. This study aimed to fabricate an efficient drug-delivery system to reduce the undesirable side effects and enable the clinical application of Ade for treating large bone defects. The fabricated poly(ε-caprolactone) (PCL)/Ade-polyvinyl alcohol (PVA)0.3/0.4 nanofibrous mats with 0.3:0.4 (w/w) ratio of Ade and PVA showed a sustained and controlled release of Ade and facilitated the osteogenic differentiation of bone mesenchymal progenitor cells (BMSCs). A larger amount of newly formed bone was observed in vivo in the cranial defects of the PCL/Ade-PVA0.3/0.4 group compared with those of the non-loaded PCL/PVA nanofibrous mats at 4 and 8 weeks after surgery. Moreover, it is the first time to confirm that Ade mediates the osteogenesis of rat BMSCs through the STAT3 signaling pathway and restrains the osteoclastogenesis of rat bone-marrow macrophages (BMMs). These results suggested that this coaxial drug-delivery system loaded with Ade provided a promising and clinically relevant platform to controlled-release Ade and address large bone defects.

1. Introduction

The turbulence caused by pathological conditions such as infection, tumor resection, and trauma results in disrupted bone homeostasis, which render bone vulnerable to defect and fracture. As a ubiquitous purine nucleoside, adenosine (Ade) was produced intracellularly and extracellularly from the metabolism of adenosine-5′-triphosphate [1–3] and involved in bone homeostasis and bone regulation [4]. However, the side effects under systemic administration, such as restraint of cardiac function, decrease in blood pressure, and accumulation of hepatotoxicity, may severely limit the therapeutic impact of adenosine [5–7]. Moreover, excessive adenosine accumulation may lead to skeletal system disorders. The conditional knockout of ecto-adenosine deaminase (ecto-ADA), a ubiquitous catabolic enzyme on the cell surface responsible for the deamination of adenosine into inosine [8], resulted in reduced trabecular bone density in mice [9]. Adenosine has a very short half-life in the interstitial fluid due to the deamination of ecto-ADA, together with the phosphorylation of adenosine to adenosine monophosphate by adenosine kinase (ADK) [6], which acts like a feedback loop to limit the adenosine concentration and hinder its clinical application, although adenosine can be considerably generated under pathological conditions such as hypoxia or inflammation [10]. Therefore, traditional administration of adenosine also cannot attain a good curative effect due to this unique metabolism pathway.

In order to conquer these problems and explore the possible signaling pathway involved in adenosine-mediated osteogenesis, the coaxial poly(ε-caprolactone) (PCL)/polyvinyl alcohol (PVA) nanofibers with a sustained and controlled release of adenosine for the aim to reduce the undesirable side effects were fabricated in this study. By separating the organic solvents from the hydrosoluble biological
molecules, the bioactivities of the loaded drugs can be perfectly maintained by the co-axial nanofibers [11,12]. Moreover, the controlled-release of adenosine can also be achieved by incorporation of adenosine into the inner layer of the coaxial nanofibers by adjusting the ratio of outer and inner materials. In our previous study, the coaxial silk fibroin/PCL/PVA nanofibrous mats have been successfully fabricated to facilitate bone repair. In this controlled-release system, bone morphogenetic protein 2 (BMP2)/PVA blending solution was embedded into the inner layer of the coaxial nanofibers and BMP2 exhibited a sustained release profile [13]. Therefore, we believe the coaxial nanofibers with controlled-release function of adenosine can conquer the disadvantages of the traditional adenosine-administrated methods by the technology of coaxial electrospinning.

Coaxial electrospinning utilizes a coaxial-nozzle configuration combining different biodegradable synthetic or natural polymers to take full advantage of the individual intrinsic advantages to manufacture coaxial fibers with unique core–sheath structure, which exhibits a highly aligned, porous, tubular, and hollow morphology. Previous study proved that coaxial nanofibers can not only control release but also preserve the bioactivities of the loaded- reagents [14,15]. Polylactic acid/collagen coaxial fibers with incorporated gentamicin have been reported to exhibit a sustained release of gentamicin and high antibacterial activity [16]. The encapsulation of bone morphogenetic protein 2 (BMP2) into poly(l-lactide-co-e-caprolactone)/collagen coaxial fibers resulted in a controlled release profile and stable bioactivity for bone tissue regeneration [17].

Among all the preferable polymers commonly used in coaxial electrospinning, hydrophobic PCL has demonstrated excellent biocompatibility, and biodegradability [18–21]. PVA is also a biodegradable polymer and has been extensively studied in tissue engineering because of its hydrophilicity, thermal stability, and advantageous mechanical property [22–25]. In this study, we fabricated coaxial PCL/PVA nanofibers with adenosine incorporated inside the nanofibers and evaluated the sustained and controlled release of adenosine.

The potential molecular mechanism of adenosine to assist osteogenesis of bone mesenchymal progenitor cells (BMSCs) and the involved signaling pathway were also explored in this study. Adenosine mediates physiologic and pharmacologic effects by interacting with the G protein coupled P1 purinergic receptors (A1, A2A, A2B, and A3) located on the cell surface [26]. Most studies have shown that adenosine and its receptors are involved in bone homeostasis and bone regeneration [27,28]. However, the molecular mechanisms downstream are not clearly understood. Here, the downstream molecular mechanism conducted by adenosine during osteogenesis and effects of the composite nanofibers on the regeneration of rat cranial defects were also investigated in this study (Scheme 1). By doing these, the undesirable side effects would be decreased and suitable application of adenosine in the bone regeneration would be attained.

2. Materials and methods

2.1. Cell culture and osteogenic or osteoclastogenic differentiation

4-week-old Sprague-Dawley (SD) rats were used in this study, and the long-bone MSCs were isolated according to previous protocols [29]. Then the harvested bone mesenchymal progenitor cells (BMSCs) from femurs and tibias were cultivated in α-MEM (Hyclone, Thermo Fisher Scientific, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Life Technologies Corporation, USA) and 1% penicillin/streptomycin (Hyclone, Thermo Fisher Scientific, USA) at 37 °C with 5% CO2. Confluent cells from passages 3–6 were cultured in osteogenic differentiation medium consisting of α-MEM supplemented with 10% FBS, 1% penicillin/streptomycin, 10 nM dexamethasone (Sigma-Aldrich, St.Louis, USA), 50 μg/ml L-ascorbic acid (Sigma-Aldrich, St.Louis, USA), and 10 mM β-glycerophosphate (Sigma-Aldrich, St.Louis, USA), which was replaced every 2 days. For osteoclastogenic differentiation, BMMs were obtained according to our previous study [30]. Cells were cultured in DMEM (Hyclone, Thermo Fisher Scientific, USA) supplemented with 10% FBS and 1% penicillin/streptomycin at 37 °C with 5% CO2, and additionally with M-CSF (50 ng/ml; PeproTech, USA) and RANKL (50 ng/ml; PeproTech, USA). The medium was replaced every 2 days.

2.2. Cell viability determined using the CCK8 assay

Cell viability was evaluated using a CCK8 kit (Dojindo, Kyushu Island, Japan). Briefly, BMSCs (5000 cells/well) were seeded in 96-well plates (Corning, Albany, USA) and were co-cultured with different concentrations of adenosine (Sigma-Aldrich, St.Louis, USA; 15 μg/ml, 30 μg/ml, 60 μg/ml, and 120 μg/ml), different concentrations of S3I-201 (Selleck Chemical, Houston, TX, USA; 25 μM, 50 μM, 100 μM, and 200 μM), or the extracted liquids of PCL/PVA or PCL/Ade-PVA(0.3/0.4) membranes; BMMs (105 cells/well) were seeded in 96-well plates and were co-cultured with RANKL (PeproTech, USA; 50 ng/ml), M-CSF (PeproTech, USA; 50 ng/ml) combined with or without different concentrations of adenosine (15 μg/ml, 30 μg/ml, and 60 μg/ml). Medium was replaced with CCK8 solution at the harvest time (1st, 3rd, and 5th days) and then incubated for 1.5 h at 37 °C, after which a microplate reader (Biotek, VT, USA) was used to generate the OD values with the absorbance recorded at a wavelength of 450 nm.

2.3. Alizarin red staining

Cells or nanofibrous membranes were washed twice with phosphate-buffered saline (PBS) and then were fixed in 4% formaldehyde for 15 min at room temperature. Then, the membranes were washed with PBS for three times, which was followed by the addition of 1% Alizarin red S staining solution (pH 4.2) and incubated for 30 min at 37 °C away from light. After subsequently rinsed three times with distilled water slightly, all the samples were prepared for microscopic observation. 10% cetylpyridinium chloride (Sigma-Aldrich, St.Louis, USA) was used to dissolve the calcium deposition for quantitative detection, which was determined by the OD value of collected solution measured at 562 nm.

2.4. RNA extraction and quantitative real-time PCR

RNA samples were isolated using an EZNA total RNA kit (Omega, Norcross, USA). Then Nanodrop2000 (Thermo Fisher Scientific, USA) was used to measure the concentration of the total RNA samples, which were used for the complementary DNA (cDNA) synthesis via Prime Script RT-PCR Kit (TaKaRa, Japan) according to the manufacturer’s instructions. RT-qPCR was performed on a Bio-Rad CFX 96 real-time PCR machine by using the All-in-One™ qPCR Mix (GeneCopoeia, Rockville, USA) to analyze the expression levels of osteogenic and osteoclastogenic related genes relative to the mRNA expression levels of GAPDH with the 2−ΔΔCT method. The primer sequences of target genes are listed in Table S1.

2.5. Western blot analysis

Cells were washed twice in PBS and then were lysed with radio immunoprecipitation assay (RIPA; Thermo Fisher Scientific, USA) buffer containing 1% phenylmethylsulfonyl fluoride (PMSF; Roche, Basel, Switzerland). After normalizing all the protein samples to 20 mg according to the measurement of protein concentration via a Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, USA), proteins were separated by 10% SDS-PAGE gels and subsequently transferred to PVDF membranes (Roche, Basel, Switzerland). The membranes were blocked with 5% skim milk in TBST solution for 1 h at room temperature, and then incubated with primary antibodies against p-STAT3 (1:2000, CST, USA), STAT3 (1:2000, CST, USA), Osterix (1:2000, Abcam, UK), Alp (1:3000, Abcam, UK), Runx2 (1:1000, Abcam, UK), and GAPDH
2.6. Immunoﬂuorescence staining

The adherent BMSCs were stimulated with dimethyl sulfoxide (DMSO; 100 μM, as vehicle control), adenosine (60 μg/ml) + DMSO (100 μM), or adenosine (60 μg/ml) + S3I-201 (100 μM) for 1 h, then were successively subjected to ﬁxation with 4% paraformaldehyde for 15 min, permeabilization with 0.5% Triton X-100 for 15 min, and blockade with 1% bovine serum albumin for 1 h at 37 °C. Subsequently all the samples were incubated with primary antibody against p-STAT3 (1:250, CST, USA) at 4 °C overnight. After incubated with anti-rabbit secondary antibody with red ﬂuorescent marker (1:500, Abbkine, USA) and counterstained of nuclei with DAPI, representative stained images were observed under an Olympus DP72 microscope (Tokyo, Japan).

Scheme 1. Schematic illustration of application of PCL/Ade-PVA(0.3/0.4) nanofibrous mats to induce bone regeneration in a rat cranial defect model. The PCL/PVA nanofibers were assembled by co-axial electrospinning with adenosine incorporated in the core of the nanofibers. The adenosine that continuously released from the ﬁbers with 0.3:0.4 (w/w) ratio of Ade and PVA could facilitate the defect healing through promotion of differentiation of BMSCs into osteoblasts via STAT3 signaling pathway and inhibition of differentiation of BMMs into osteoclasts.

2.7. Tartrate-resistant acid phosphatase (TRAP) staining

After being ﬁxed with 4% paraformaldehyde for 15 min, the cells were incubated with TRAP solution using kit 387-A (Sigma-Aldrich, St.Louis, USA) following the manufacturer’s instructions for 10 min at room temperature in the dark, which was followed by counterstain nuclei with DAPI (Beyotime, Hangzhou, China) for 5 min away from light. Finally, the samples were washed with PBS solution slightly and stored in PBS solution for further observation under light microscopy.

2.8. Preparation of PCL/Ade-PVA composite mats

PCL/Ade-PVA composite nanofibrous mats were fabricated through the co-axial electrospinning technology according to our previous study [31]. Briefly, the sheath solution (10% PCL, w/w) was firstly prepared by dissolving 10 g PCL (70,000–90,000 DA, Sigma-Aldrich, St.Louis, USA) in 100 g hexaﬂuoroisopropanol (HFIP) (Aladdin Co., China). Then, the core solutions with 0.1/0.6, 0.2/0.5, 0.3/0.4 and 0.4/0.3 ratios of adenosine and PVA were made by dispersing 0.1, 0.2, 0.3, and 0.4 g adenosine in 10 ml PVA (85,000–14,000 DA, Sigma-Aldrich, St.Louis, USA) aqueous solutions containing 0.6, 0.5, 0.4, 0.3 g PVA,
respectively. After magnetic stirring for 2 h and ultra-sonication for 0.5 h in an ice bath, the adenosine-PVA solutions were used as a core-solution. 10 ml PVA solution without adenosine incorporation was used as the Empty control group. The co-axial electrospinning system was equipped with a metal collector, a high DC voltage of 20 kV, the inner and outer spinners. The sheath- and core-solution were transported into the outer and inner syringes, respectively. All the electrospinning processes were performed at 27 °C and 60% humidity.

To visualize the distribution of the adenosine-PVA solution in the composite nanofibers, 10 mg calcein and 10 mg rhodamine B were added into core- and sheath solution, respectively. Then, the calcein/Ade-PVA solutions with a green color and the rhodamine B/PCL solution with a red color were observed by confocal microscopy (LEICA SP8 STED, Germany).

2.9. Characterizations

The morphology of the PCL/Ade-PVA samples was observed by a scanning electron microscopy (SEM, ZEISS SIGMA, Germany). The diameter of 100 different fibers per image was measured to determine the mean diameter of the PCL/Ade-PVA composite mats using Nano measurer 1.2 software. The dynamic water contact angles (WCA) of the PCL/Ade-PVA composite nanofibrous mats were evaluated by the drop shape analysis equipment (USA KINO Industry Co., USA). The stress-strain responses of the PCL/Ade-PVA composite mats were analyzed by an ETMS502A tensile tester (Shenzhen Wance Instrument Co., Ltd., China) after all the samples were cut into 3 × 1 cm. The cytocompatibility of the prepared composite mats was determined by fluorescent Live/Dead staining using a LIVE/DEAD™ Cell Imaging Kit (Thermo Fisher Scientific, USA) and then observations under a confocal laser scanning microscope (Olympus, Tokyo, Japan) after cultured with the seeding BMSCs for 3 days.

2.10. High performance liquid chromatography (HPLC) analysis of released adenosine content

Five replicates of the round PCL/Ade-PVA(0.3/0.4) composite nanofibrous mats (diameter = 5 mm), which were as same as that used in animal experiments, were incubated in 3 ml distilled water in a 37 °C water bath with slow shake for 1, 15, 30, 45, and 60 days. At each time interval, the extract liquid was removed with fresh water replaced, and 1 ml was used for HPLC analysis using an Agilent 1200 HPLC System combined with a Hisep C18 column (4.6 × 250 mm, 5 μm, Weltech, Wuhan, China). Samples were eluted by the mobile phase that consisted of 10 mmol/L potassium dihydrogen phosphate and methyl alcohol in a gradient sequence for dehydration and subsequently embedded in paraffin blocks. The embedded samples were sectioned 5 mm thick from the center of the repair site and stained with haematoxylin-eosin (HE) staining, Masson’s trichrome staining and immunohistochemistry staining. For immunohistochemistry staining, the primary antibody against Coll I (1:500; Abcam, UK) was used and the expression of Coll I in the defect site areas was visualized by 3, 3-diaminobenzidine tetrahydrochloride (DAB) (Zhongshan Biotechnology, Ltd., China). Lastly, the images of all the stained slices were observed and captured using an optical microscope (Olympus DP72, Tokyo, Japan).

2.13. Statistical analysis

All experiments were repeated independently at least six times with results analyzed via GraphPad Prism software 3.06 and reported as mean and standard deviation. Statistical evaluation was performed through Two-way ANOVA and Students’-test. Values of $P < .05$ were considered significantly different.

3. Results and discussion

3.1. Influence of adenosine on the osteogenic differentiation of BMSCs

To evaluate the effect of adenosine on the osteogenesis of BMSCs in vitro, Alizarin Red staining was performed to observe the deposition of calcium nodules after treatment with the growth medium supplemented with different concentrations of adenosine (Fig. S1A, B). Similar to the results in a previous study, in which adenosine can solely drive the differentiation of human induced pluripotent stem cells (iPSCs) into osteoblasts [32], we verified that 60 μg/ml adenosine can significantly enhance the formation of mineralized nodules compared with the lower concentration groups (15 μg/ml and 30 μg/ml, $p < .05$). However, no significant difference was observed between the 60 μg/ml adenosine group and conventional mineralized induction medium group ($p > .05$). In our study, at higher concentration of adenosine (120 μg/ml), the osteogenic efficacy became lower. This phenomenon may be explained by the fact that the influence of excessive exogenous adenosine on osteogenic differentiation may be restricted because of the enzymolysis of adenosine mediated by ecto-ADA and ADK [6,8]. Another possible explanation is that high adenosine levels can lower the sensitivity and specificity of relevant adenosine receptors participating in the modulation of osteoblast function [33]. To evaluate the cytotoxicity of adenosine, CCK8 assay was performed to test the viability of the BMSCs after treatment with 15, 30, 60, or 120 μg/ml of adenosine. No significant differences were detected among the groups ($p > .05$) (Fig. S1C), suggesting that exogenous adenosine had no significant cytotoxic effects on the BMSCs.
3.2. Participation of STAT3 signaling in the adenosine-mediated osteogenesis in BMSCs

Prior studies have shown the importance of STAT3, which was originally defined as a cytoplasmic transcription factor and further identified to play pivotal roles in different tissues, particularly in the bone [34]. In our previous study, we have also shown that blockade of JAK2/STAT3 signaling by AG490, a selective JAK2 inhibitor, results in the suppression of hypoxia-induced osteogenesis of BMSCs and bone defect healing [35]. Given that almost all STAT genes and proteins are focused on the adenosine receptors when the potential mechanisms in the osteoblast metabolism were considered. A2AR acted as a medium for adenosine to accelerate the proliferation of mouse BMSCs [36]. During the osteoblast differentiation of the BMSCs, the A2AR signal was enlarged to facilitate the alkaline phosphatase activity [37]. A2BR KO mice showed a reduction in the osteoblast differentiation, osteoblast-related gene expression, and calcium deposition in the mesenchymal cells [38]. By contrast, our study demonstrated a possible downstream signal transduction mechanism of adenosine in osteogenesis, which depended on the activation of STAT3 signaling.

3.3. Effect of adenosine on osteoclast precursors

The maintenance of bone tissue homeostasis depends on the favorable skeleton turnover, including the bone formation and bone resorption mediated by osteoblasts and osteoclasts, respectively. With unique and impressive morphology, a mature osteoclast is a kind of multinuclear macrophage [39] and positively expresses tartrate-resistant acid phosphatase (TRAP). Therefore, we performed TRAP staining to evaluate the effect of adenosine on the osteoclast differentiation of rat bone-marrow macrophages (BMMs), which was induced by macrophage colony stimulating factor and receptor activator of nuclear factor (NF)-κB ligand (Fig. 3A–C). As shown in the Figs. 3, 15 or 30 μg/ml adenosine did not affect the formation of TRAP-positive multinucleated cells (Fig. 3A–C). By contrast, 60 μg/ml adenosine obviously diminished the osteoclastic differentiation of BMMs (Fig. 3D), resulting in the distinct reduction in the mature osteoclasts (Fig. 3E, p < .05). Meanwhile, 60 μg/ml adenosine promoted cell proliferation at 3 and 5 days (Fig. 3F, p < .05). These results indicated that 60 μg/ml adenosine may inhibit osteoclastic differentiation while promoting the expression of the osteoblast-specific markers ALP, ColI, Osterix, and Runx2, and these effects can be inhibited by S3I-201 (Fig. 2G–J, p < .05). The expression of these proteins showed the same tendency with the gene expression profile (Fig. 2K). Previous studies have mostly focused on the adenosine receptors when the potential mechanisms in the osteoblast metabolism were considered. A2AR acted as a medium for adenosine to accelerate the proliferation of mouse BMSCs [36].

Fig. 1. Adenosine promoted STAT3-mediated osteogenesis of BMSCs.

BMSCs were treated with the indicated concentrations of adenosine for 0.5, 1, and 2 h (A), or DMSO (100 μM), SCI-201 (100 μM), adenosine (60 μg/ml) combined with DMSO (100 μM), and adenosine (60 μg/ml) combined with SCI-201 (100 μM) for 1 h, representative immunofluorescent photos displayed the nuclear levels of STAT3 (red) (C–K). Ade, adenosine. S3I, S3I-201. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
proliferation of osteoclast precursors. These results provide a new understanding of the mechanism of adenosine during bone healing and establish a foundation for the further development of clinical treatment using adenosine.

3.4. Characteristic of the PCL/adenosine-PVA nanofibrous mats

Considering that the promotion of adenosine on the osteogenesis of BMSCs is dose-dependent, and high concentration of adenosine has restricted this osteogenesis, we fabricated a coaxial nanofibrous mat for the controlled release of adenosine with appropriate concentrations to promote new bone formation.

The morphology of the fabricated PCL/Ade-PVA composite nanofibrous mats was characterized by a scanning electron microscope (SEM). Fig. 4 shows that the PCL/Ade-PVA composite nanofibrous mats had highly porous 3D net-like structures (Fig. 4A–D). The PCL/PVA nanofibrous mat without adenosine showed a nonuniform diameter distribution (Fig. 4E, 735 ± 610 nm). With the incorporation of adenosine, the diameters of PCL/Ade-PVA(0.1/0.6) (Fig. 4A, 1019 ± 535 nm), PCL/Ade-PVA(0.2/0.5) (Fig. 4B, 1424 ± 731 nm), PCL/Ade-PVA(0.3/0.4) (Fig. 4C, 1398 ± 280 nm), and PCL/Ade-PVA(0.4/0.3) (Fig. 4D, 2019 ± 1052 nm) nanofibers showed a more uniform distribution compared with that of the PCL/PVA group. Among all groups, the PCL/Ade-PVA(0.3/0.4) composite nanofibrous mat exhibited the most uniform distribution of fiber diameter (Fig. 4F–J). This result suggested that the most suitable ratio of adenosine to PVA was 0.3:0.4. Therefore, the PCL/Ade-PVA(0.3/0.4) composite nanofibrous mat was used in the following experiments.

Fig. 2. SCI-201 inhibited adenosine-induced osteogenesis. Representative macroscopic and microscopic images of Alizarin Red staining for evaluation of the osteogenesis induced by respective groups for 21 days in BMSCs (A–F). Real-time PCR and Western blot analysis further revealed that SCI-201 (100 μM) not only inhibited osteoblast-related genes ALP, Col1, Osterix, and Runx2 mRNA levels (G–J), but also suppressed their protein levels induced by adenosine (60 μg/ml) in BMSCs (K). S3I, S3I-201. MM, mineralized medium. Ade, adenosine. *P < .05. The Students’ t-test.

The stress–strain curves (Fig. 5A) show that the PCL/PVA composite nanofibrous mats were broken at 3.52 ± 0.56 Mpa when the elongation reached approximately 155.41% ± 43.24%. With the incorporation of adenosine, the elongation at break of the PCL/Ade-PVA(0.3/0.4) composite nanofibrous mats did not remarkably change (124.93% ± 29.23%, p > .05). However, the stress at break of the PCL/Ade-PVA(0.3/0.4) group significantly increased and reached 7.1 ± 1.33 Mpa (p < .05). These results indicated that adenosine incorporation improved the mechanical properties of the PCL/PVA coaxial nanofibrous mats. As shown in Fig. 5B, the water contact angles (WCAs) of the PCL/PVA composite mats were 87.5° ± 8.36°, 71.5° ± 8.36°, and 30.28° ± 8.36° at 20, 60, and 100 s, respectively. With the incorporation of adenosine, the WCAs of the PCL/Ade-PVA(0.3/0.4) composite nanofibrous mats were decreased to 73.5° ± 8.36°, 68.5° ± 6.36°, and 17.28° ± 3.36° at 20, 60, and 100 s, respectively. Slightly longer time was observed for the PCL/Ade-PVA(0.3/0.4) nanofibrous mats (118 s) to completely absorb the water droplets compared with that of the PCL/PVA mats (108 s, Fig. S4A). However, this discrepancy had no significant statistical difference (Fig. S4B, p > .05). These results demonstrated that adenosine incorporation had little influence on the hydrophilicity of the PCL/Ade-PVA(0.3/0.4) nanofibrous mats. Confocal microscopy was used to observe the core–sheath structure of the co-axial PCL/Ade-PVA nanofibers. As shown in Fig. 5D, the PVA or Ade-PVA core with a green color was uniformly distributed at
the center of the PCL/PVA and PCL/Ade-PVA(0.3/0.4) nanofibers with red color. The cytocompatibility of the PCL/Ade-PVA nanofibrous mats was evaluated by Live/Dead staining. From the results in Fig. 5E and the negative and positive controls exhibited in Fig. S5, BMSCs seeded onto the PCL/PVA and PCL/Ade-PVA(0.3/0.4) nanofibrous mats exhibited a green color. The CCK-8 assay showed that the extract liquid from both nanofibrous mats exhibited no evident cytotoxicity to reduce cell activities in BMSCs (Fig. S6). Thus, these results demonstrated that the PCL/PVA and PCL/Ade-PVA(0.3/0.4) nanofibrous mats were not cytotoxic to the BMSCs. The morphology of the BMSCs seeded onto the PCL/PVA and PCL/Ade-PVA(0.3/0.4) (Fig. 5F) nanofibrous mats was examined by an SEM. The cells on the PCL/PVA nanofibrous mat were spindle shaped, contrary to the polygon-shaped cells on the PCL/Ade-PVA(0.3/0.4) nanofibrous mat. These results demonstrated that adenosine might promote the stretching of cells.

3.5. Drug release of adenosine-loaded PCL/PVA co-axial nanofibrous mats in vitro

To determine the drug releasing effect of the fabricated PCL/Ade-PVA(0.3/0.4) nanofibrous membranes, the extract liquid of the membranes at various time intervals (1, 15, 30, 45, and 60 days) was collected and then applied to HPLC assay. Representative chromatograms of adenosine retention are shown in Fig. S7. The samples (Fig. S7B–F) showed similar peak eluting time of ~12.4 min to the adenosine standard (150 μg/ml) (Fig. S7A), indicating that we have successfully
achieved the sustained and controlled diffusion of adenosine from the PCL/Ade-PVA(0.3/0.4) nanofibrous mats for up to 60 days. Similar to a silk-based adenosine delivery system with sustained release of adenosine due to the degradation of the coated silk [40] and to the core-shell gel beads with the hydrophobic polymer coating that increased the release time of proteins [41], the slow release in this study can be attributed to the slow degradation of hydrophobic PCL. The quantification of the adenosine release from the nanofibrous mats is shown in Fig. 5C. Similar to other typical release profiles of layer-by-layer drug-delivery systems [42,43], an initial burst release of adenosine was observed in the PCL/Ade-PVA(0.3/0.4) nanofibrous mats on day 1, during which the concentration of the released adenosine was 146.37 ± 11.18 μg/ml. This phenomenon may be due to the fact that the adenosine on the fiber surfaces quickly diffused after the water infiltration [10]. Afterward, the release rate of adenosine became stable as PCL protected adenosine in the core from being released into the outer environment. With the slow degradation of the shell of PCL and the gradual exposure of water-soluble PVA, the encapsulated adenosine was continuously released, sustaining a linear release profile. The cumulative release concentrations on days 15, 30, 45, and 60 were 224.48 ± 14.45, 296.02 ± 17.05, 326.67 ± 11.30, and 359.31 ± 15.23 μg/ml, respectively (Fig. 5C). During the drug-controlled-release phase, the cumulative release concentration at each time interval was within the effective range of concentration as confirmed by the results of previous in vitro experiments (Fig. S1). These results not only indicated that the PCL/PVA coaxial drug release system showed the characteristic biphasic behavior that performed a relatively constant release after an initial burst release [44,45] but also provided the foundation for application of the PCL/Ade-PVA(0.3/0.4) nanofibrous mats in the following animal study.

3.6. In vivo bone formation of calvarial defects

To further explore the effects of PCL/Ade-PVA(0.3/0.4) composite nanofibrous membranes on the repair of bone defect, SD rat cranial bone defects were first established and implanted with the PCL/PVA and PCL/Ade-PVA(0.3/0.4) nanofibrous membranes. Micro-CT was used to analyze the new bone formation after 4 and 8 weeks of healing. As shown in Fig. 6A–J, a small amount of bone was formed on the boundary of the bone cavity in the sham groups after 4 and 8 weeks (Fig. 6A, F), whereas PCL/PVA groups showed more calcific deposition (Fig. 6B, G). These results suggested that the non-loaded PCL/PVA nanofibrous membrane can induce osteogenesis to a certain degree. The largest amount of newly-formed bone was observed in the defect size covered by the modified PCL/PVA membranes incorporated with adenosine in the PCL/Ade-PVA(0.3/0.4) group (Fig. 6D, I). In terms of the PCL/Ade-PVA(0.3/0.4) membranes that were intraperitoneally injected with S3I-201 at a dose of 10 mg/kg every two days, the osteogenesis effect at the defect site of the PCL/Ade-PVA(0.3/0.4) groups was remarkably suppressed at both 4 and 8 weeks post-implantation (Fig. 6E,
J). However, S31–201 treatment showed little effect on the bone formation of the bare PCL/PVA group (Fig. 6C, H). The quantification of the bone mineral density and the percentage of BV/TV further confirmed that, although the PCL/PVA groups showed more bone regeneration than the sham groups, PCL/Ade-PVA (0.3/0.4) groups exhibited the most robust osteogenic efficacy, which could be reversed by the intraperitoneal administration of S3I-201 at 4 and 8 weeks (Fig. 6K–N, p < .05). Histology assays, including HE, Masson trichrome staining, and immunohistochemical staining, of type I collagen (Col1) protein were further adopted to confirm the new bone formation and evaluate the newly formed bone morphology as shown in Fig. 7A–D and Fig. S8. 90% of the bone matrix is comprised of Col1 during the bone development, which could promote adherence and stimulate osteogenic differentiation of mesenchymal stem cells [46]. Moreover, Col1 is functionalized mainly during the early stages of bone healing to induce

Fig. 6. The effects of fabricated nanoﬁbrous membranes on new bone formation in the cranial defect model of SD rats. Micro-CT images of bone formation in sham group (A, F), the implantation of PCL/PVA nanoﬁbrous membranes (B, G) with intraperitoneal administration of SCI-201 (10 mg/kg) every two days (C, H), the implantation of PCL/Ade-PVA(0.3/0.4) nanoﬁbrous membranes (D, I) with intraperitoneal administration of SCI-201 (10 mg/kg) every two days (E, J) at both 4 and 8 weeks. Quantification of the bone formation from the micro-CT images (K–N). *P < .05. The Students’ t-test.
osteoblastic differentiation and form mineralized bone tissues [47]. In our current study as shown in Fig. 7B, D, both at 4 and 8 weeks post-implantation, the PCL/PVA group showed elevated Col1-positive areas compared with the sham group, but no significant difference was found compared with that of the PCL/PVA group combined with S3I-201 administration. This result suggested that STAT3 signaling may not be involved in the bone regeneration induced by the PCL/PVA membranes. Moreover, higher Col1 expression level was found within the defect regions in the PCL/Ade-PVA(0.3/0.4) group than that of the pure PCL/PVA group, but the intervention by S3I-201 led to reduced Col1 expression (Fig. 7B, D). These results indicated that the contribution of PCL/Ade-PVA(0.3/0.4) nanofibrous membranes to osteogenesis in bone defects may be primarily related to the release of adenosine that activated the STAT3 signaling. These results also agreed with those of Alizarin Red staining of BMSCs cultured with the PCL/Ade-PVA(0.3/0.4) nanofibrous membranes in vitro (Fig. S9).

To evaluate the possible side effects brought by adenosine application, the hemodynamics and serum functional biomarkers of animals in all groups were evaluated after creation of cranial defects and intravenous injection of adenosine or 0.9% saline solutions. Although adenosine was commonly used to treat the patients with myocardial infarct in large-scale clinical trials [48,49], this agent caused unfavorable hemodynamic effects, such as hypotension and bradycardia [50]. Therefore, it is necessary to release adenosine into the physiological environment in a controlled rate for minimizing the adverse side effects of systemic administration. As shown in Fig. S10, the intravenous injection of adenosine resulted in the decrease of the mean blood pressure and heart rate at the first 10 min of injection (p < .05) and sustained for another 5 min when compared with that of the sham group, which is in accordance with the results of the previous study that intravenous injection of adenosine decreased blood pressure and heart rate [7]. No significant difference in mean blood pressure or heart rate was observed among the control, sham, PCL/PVA, PCL/PVA + S3I and PCL/Ade-PVA(0.3/0.4) + S3I groups (p > .05). In addition, the activity of alanine aminotransferase (ALT) and aspartate transaminase (AST) enzymes were tested on day 7, 14, and 21 after surgery (Table S2) to examine the hepatotoxicity in consideration of the fact that ADK exists in liver with a highest level, and the ADK-mediated phosphorylation of adenosine is believed to be one of the primary route of adenosine metabolism [51]. However, no significant difference was found among all groups during the whole time period (p > .05), which indicated that neither intravenous injection nor controlled release of adenosine led to the obvious hepatotoxicity. Therefore, the above mentioned results suggested that our fabricated core-shell nanofibers for adenosine delivery could significantly reduce the undesirable hypotension and bradycardia induced by systemic administration.
4. Conclusions

In summary, we developed a novel drug-delivery system for adenosine by using PCL/PVA nanofibrous membranes via coaxial electrostatic spinning. The treatment using adenosine was based on our discovery that adenosine could promote the osteogenic ability of BMSCs by activating the STAT3 signaling pathway and exert a negative effect on the osteoclastogenesis of osteoclast precursors. The in vivo tests clearly demonstrate that PCL/PVA coaxial membrane is a promising system for the sustained-release of adenosine to restore large bone defects void of side effects, especially the undesirable hypotension and Bradycardia, induced by systemic administration of adenosine.

Declaration of Competing Interest

The authors declare no competing financial interest.

Acknowledgements

This work was mainly supported by National Natural Science Foundation of China (51873157, 81771051 and 81800943), and partially supported by the Natural Science Foundation of Hubei Province of China (No.2018CFB497).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jconrel.2019.12.048.

References


